Pictet Asset Management Holding SA Decreases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Pictet Asset Management Holding SA reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,584 shares of the company's stock after selling 3,401 shares during the quarter. Pictet Asset Management Holding SA owned about 0.17% of Medpace worth $17,802,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Medpace in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the fourth quarter valued at $31,000. Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the period. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace currently has a consensus rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Price Performance

Shares of NASDAQ MEDP traded down $17.00 during mid-day trading on Friday, reaching $287.11. 833,195 shares of the company's stock traded hands, compared to its average volume of 307,847. The business has a 50-day simple moving average of $331.56 and a 200 day simple moving average of $337.32. The stock has a market cap of $8.75 billion, a P/E ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a 1-year low of $282.42 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.